Our Journey

The SMT journey has been a pledge, a pledge to save millions. With people in over 75 countries benefitting from our minimally invasive coronary intervention devices, we have truly created a journey that has made a difference. We move ahead with the outlook to cover complete cardiovascular treatment support, each day.

2020
SMT announces entry in Structural Heart Segment with the acquisition of Vascular Concepts and Vascular Innovations.
2019
Talent Trial gets published in The Lancet journal. The Journal is very well renowned with an impact factor more than 59 [2018]. The Lancet is currently ranked second among 150 journals in the 'General & Internal Medicine' subject category.
2018
The Talent Trial results presented in late-breaking clinical trial session at TCT 2018, San Diego, USA.
Results: The Talent Trial non-inferiority proved there was 61% reduction in clinically driven TLR in per-protocol analysis as published in The Lancet.
Talent Result
2018
SMT launches Supraflex Cruz (Sirolimus Eluting Cobalt Chromium Coronary Stent System), which provides ultimate deliverability through its breakthrough design; making it truly convenient for the Interventional Cardiologists to treat even the most complex cases with ease.
2017

After establishing itself in India and Europe, SMT gets into a strategic partnership with Cardinal Health Inc, US and brings Cordis products to India.
2017
Morgan Stanley quickly follows Samara Capital by making its own investment by supporting the SMT story & mission.
2016
As SMT grows leaps & bounds in a decade, it also attracts the attention of some key investors. SMT receives investment from Samara Capital.
2016
SMT Ireland
SMT launches its operations in Europe by setting up state-of-the-art R&D centre in Galway, Ireland.
2016
SMT glide
SMT further extends its product basket by launching:
  • TetriflexTM (Sirolimus Eluting Cobalt Chromium Coronary Stent System)
  • SMT Glide Diagnostic Catheter
2016
After launching a slew of cutting edge products in India, Talent trial gets initiated in 7 countries with 1435 patients in 23 centres across Europe, benchmarking Supraflex* to Xience.*
2015
SMT launches 3 new products:
  • RenofitTM (Balloon Expandable Cobalt Chromium RENAL and BILIARY Stent System)
  • TetrilimusTM (Everolimus Eluting Cobalt Chromium Coronary Stent System)
  • WilmaTM (PTCA Dilatation Catheter)
2014
SMT achieves a successful vertical integration and an even greater control over product performance & quality by initiating the production of Balloon Catheters.
Balloon Catheters
2014
SMT delivers another breakthrough in the Indian stent manufacturing industry by delivering Everoflex; A DES specifically designed to prevent late stent thrombosis.
2013

Within a year SMT receives yet another CE approval for Supraflex, which brings the company at par with some of the leading stent manufacturers in the world.
2012
SMT receives CE approval for the coronary stents systems Supralimus & Supralimus Core.
Supralimus Logo
Supralimus Core Logo
2011
SMT starts its second state-of-the-art manufacturing plant at Surat SEZ to keep up with the growing demand.
2005
SMT becomes a pioneer in Interventional Cardiology by becoming the first company in the world to receive the CE certification for a DES with a biodegradable polymer on Infinnium.
CE Certification
2004
SMT successfully initiates exports to
Latin America and South Asia.
Latin America
2002
Infinnium
SMT launches its first Drug Eluting Stent - Infinnium.
2001
Matrix, the first commercialized product, by SMT receives the coveted European CE approval.
Matrix
2000
SMT begins production at its
Daman, India plant.
daman plant
1999
Matrix 1999
SMT launches its first product Matrix.
1999
Daman Plant
SMT establishes its first plant at Daman, India.
1998
Mr. Dhirajlal Kotadia

Mr. Kotadia succeeds in establishing STPL as the backbone of the Indian Diamond Manufacturing industry and with this as a platform, looks to take on and solve a variety of societal & economical challenges around him.

One fateful night in Surat, Mr. Kotadia stopped at a pharmacist to buy some medicines. While waiting, he witnessed a poor elderly man show up at the counter with his prescription. When the elder gentleman started crying due to inability to pay the Rs. 473 bill for the medicines, Mr. Kotadia paid it without a hesitation. And while paying the bill, he thought to himself that, "A man's inability to pay for the most basic & critical medications is the more dire of societal issues".

This incident ignited a spark in Mr. Kotadia's mind to manufacture critical life saving devices, which are affordable to the common man. And, thus began the journey of Sahajanand Medical Technologies (SMT) with, "Pledge to Save Millions".

1992
STPL
Mr. Dhirajlal Kotadia, an engineer not by qualification but rather by self-education & talent, had a very humble beginning of being a pen salesman. Beneath this gentleman was a dedicated & hardworking professional with a soft heart towards humanity. With an ambition to do something for India, he established Sahajanand Technologies Pvt Ltd (STPL) to advance the capabilities of the Indian Diamond Manufacturing industry through best in class, advanced manufacturing technologies.

* Specifications are subject to modification, revision and improvement.
Supraflex is a registered trademark of Sahajanand Medical Technologies or its affiliates. Xience is a trademark or registered trademark of the Abbott Group of Companies.